Akoya Biosciences’ history represents the rapid advancement driving the field of multiplexed biomarker analysis and immunofluorescence tissue analysis. Today’s Akoya portfolio spans the spectrum from powerful tools for the discovery of important biomarkers to clinical research applications.

Akoya Biosciences was founded in 2015 to commercialize the CODEX System to enable ultra-high multiplexing for biomarker discovery. The fundamental CODEX technology was developed in the lab of Dr. Garry Nolan at Stanford University, who has served as a pioneer in technological and computational methods to enable a better understanding of tissue architecture and its contribution to disease pathology.

The Phenoptics™ technology was originally conceived and developed by Cambridge Research & Instrumentation, co-founded by Peter Miller and Cliff Hoyt, acquired by Caliper in 2010, which was subsequently acquired by PerkinElmer in 2011. The Phenoptics™ technology was promptly adopted as the industry standard for multiplexed tissue analysis for translational and clinical research. 

The partnership between PerkinElmer and Telegraph Hill Partners, announced in November of 2018, created the current Akoya Biosciences. This combined portfolio of complementary technologies will continue to fuel groundbreaking advancements in cancer immunology, immunotherapy and a wide range of pathology research.

Watch the Akoya on-demand webinar and find out more about spatial phenotyping:
https://www.akoyabio.com/webinars/